Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Tereza Planck

Physician

Default user image.

The Effect of Radioiodine Treatment on TRAb, Anti-TPO, and Anti-TG in Graves' Disease

Author

  • Ola Lindgren
  • Pernilla Asp
  • Anna Sundlöv
  • Jan Tennvall
  • Bushra Shahida
  • Tereza Planck
  • Peter Åsman
  • Mikael Lantz

Summary, in English

Background: In Graves' disease (GD), immunocompetent cells infiltrate thyroid tissue with release of TSH-receptor antibodies (TRAb), and radioiodine treatment is known to elicit an immune response with an increase in TRAb. Objectives: The aim was to study if all patients treated with radioiodine respond with a release of TRAb, anti-thyroperoxidase (anti-TPO), and anti-thyroglobulin (anti-TG). Methods: This is a prospective observational study. GD patients (n = 131) were admitted for treatment with radioiodine. Thyroid antibodies were measured before and 3 months after iodine-131 treatment. Results: After 3 months, a fold change > 1.1 was found in 66% of the GD patients, while the remaining 34% did not have a change or decrease in in TRAb. Anti-TPO and anti-TG also increased; the former showed an increase in 73% and the latter of 52%, while 27 and 48% decreased/were unchanged. A significant positive correlation was found between TRAb and anti-TPO, but not between TRAb and anti-TG. In the group with an increase in TRAb, the median fold change was 5.1, but there were no additional effects of tobacco smoking. The proportion of females below the median age (51.5 years) was significantly higher in the group that increased in TRAb compared to the one that decreased/was unchanged (66 vs. 34%). Conclusions: Treatment with radioiodine elicits an increase in thyroid antibodies, but not in all GD patients. The proportion of responders varied and was affected by age, resulting in a stronger immune response at younger age. However, there were no additional effects of smoking.

Department/s

  • Medicine, Lund
  • EXODIAB: Excellence in Diabetes Research in Sweden
  • Tumor microenvironment
  • Genomics, Diabetes and Endocrinology
  • Ophthalmology (Malmö)

Publishing year

2019-01-03

Language

English

Pages

64-69

Publication/Series

European Thyroid Journal

Volume

8

Issue

2

Document type

Journal article

Publisher

Karger

Topic

  • Rheumatology and Autoimmunity

Keywords

  • Anti-TG
  • Anti-TPO
  • Graves' disease
  • Radioiodine
  • TRAb

Status

Published

Research group

  • Genomics, Diabetes and Endocrinology
  • Ophthalmology (Malmö)

ISBN/ISSN/Other

  • ISSN: 2235-0640